← All trials
NCT05887167
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- Dec 15, 2025
- Completion date
- Dec 15, 2026
- First posted
- Jun 2, 2023
- Last posted
- Nov 14, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cedars-Sinai Medical CenterLead sponsor
- Cedars-Sinai Medical CenterOverall official - principal investigator
- Cedars-Sinai Medical CenterSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.